Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 265
interventional 192
Observational 67
Registry 6

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 63
Drug|placebo 56
Other 23
Biological 8
Procedure 6
Device 5
Behavioral 4
Biological|Drug 4
Biological|placebo 3
Device|Procedure 2
Drug|Procedure 2
Other|placebo 2
Other|Procedure 2
Biological|Diagnostic Test|Drug|placebo 1
Biological|Drug|Other|Procedure 1
Biological|Other 1
Device|placebo 1
Diagnostic Test 1
Dietary Supplement 1
Drug|Genetic 1
Drug|Other 1
Drug|Other|Procedure|Radiation 1
Drug|Radiation 1
placebo|Procedure 1
Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 66
France 25
NA 10
Canada 8
United Kingdom 7
Germany 6
Japan 5
Brazil 4
Turkey 4
India 3
Netherlands 3
United States|Canada 3
United States|Canada|United Kingdom 3
Egypt 2
Greece 2
Italy 2
Mexico 2
United States|Australia 2
Australia|France|Germany|Italy|Poland|United Kingdom 1
Austria 1
Belgium|France|Germany|Netherlands|Portugal|Spain 1
Bulgaria|France|Germany|Italy|Netherlands|Poland|Slovenia|Spain|Switzerland|United Kingdom 1
Chile 1
China 1
France|Germany|United Kingdom 1
Germany|Hungary|Italy|Poland|Spain|United Kingdom 1
Germany|Sweden|Switzerland 1
Indonesia 1
Iran, Islamic Republic of 1
Korea, Republic of 1
Norway 1
Singapore 1
Sweden 1
Switzerland 1
Thailand 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|China|Czechia|Denmark|Finland|France|Germany|Greece|Hungary|India|Ireland|Israel|Italy|Japan|Malaysia|Mexico|Netherlands|Norway|Poland|Portugal|Spain|Sweden|Switzerland|Thailand|United Kingdom 1
United States|Argentina|Australia|Belgium|Canada|France|Germany|Italy|Mexico|Poland|Spain|Switzerland|United Kingdom 1
United States|Argentina|Belgium|Bulgaria|Canada|Denmark|France|Germany|Greece|Hungary|Italy|Japan|Lithuania|Mexico|Netherlands|Poland|Portugal|Puerto Rico|Romania|Spain|Switzerland|United Kingdom 1
United States|Argentina|Belgium|Estonia|France|Germany|Italy|Mexico|Poland|Romania|Russian Federation|Ukraine|United Kingdom 1
United States|Australia|Belarus|Bulgaria|Canada|Chile|Colombia|Croatia|Czech Republic|Denmark|Finland|Germany|Hungary|India|Italy|Poland|Russian Federation|Ukraine 1
United States|Australia|Belgium|Canada|Czechia|France|Germany|Hungary|Italy|Japan|Netherlands|New Zealand|Switzerland|Turkey|United Kingdom 1
United States|Australia|Canada|Germany|Israel|Japan|Korea, Republic of|Netherlands|Poland|Spain|Switzerland|United Kingdom 1
United States|Belgium|Germany|Italy|Spain|United Kingdom 1
United States|Belgium|Italy|Spain|United Kingdom 1
United States|Canada|France|Germany|Israel|Italy|Korea, Republic of|Netherlands|Sweden|Switzerland|United Kingdom 1
United States|Canada|France|Germany|United Kingdom 1
United States|Canada|Italy 1
United States|Canada|Netherlands|United Kingdom 1
United States|France|Germany|Israel|Italy|Netherlands|Sweden|Switzerland|United Kingdom 1
United States|France|Italy|Switzerland|United Kingdom 1
United States|Germany|Italy|Switzerland|United Kingdom 1
United States|India 1
United States|Poland|Spain 1

Sites per Study

Site_count Study_Count
1 119
2 10
3 5
4 6
5 2
6 2
7 1
9 1
10 4
11 1
12 5
13 2
14 3
15 2
16 2
17 6
18 1
19 1
22 1
24 1
25 1
27 1
28 1
29 2
30 2
36 1
44 1
49 1
50 1
59 1
74 1
77 2
83 1
195 1

Phase

Phase Study_Count
Phase 2 58
N/A 55
Phase 3 29
Phase 1 15
Phase 1/Phase 2 15
Phase 2/Phase 3 9
Phase 4 7
Early Phase 1 4

Number of Arms

Number_of_Arms Count_of_Studies
1 55
2 98
3 17
4 4
5 2
6 2
9 1
NA 13

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 10.0 4.0000 6.00000 3.00000 1.00000 22.00000 6.0000 15.00000
1st Qu. 17.5 22.5000 17.50000 10.00000 20.00000 26.00000 40.0000 19.00000
Median 21.0 40.0000 28.00000 17.00000 31.50000 56.00000 84.0000 25.00000
Mean 20.5 100.6182 56.06667 18.35714 49.12069 70.55556 130.4828 30.28571
3rd Qu. 24.0 104.5000 37.50000 23.00000 62.25000 116.00000 188.0000 32.00000
Max. 30.0 629.0000 264.00000 47.00000 168.00000 132.00000 580.0000 70.00000

Trial Group Type

group_type Group_Count
Experimental 195
Placebo Comparator 68
Active Comparator 43
Other 26
No Intervention 13
NA 13
Sham Comparator 4

Intervention Model

intervention_model Study_Count
Parallel Assignment 109
Single Group Assignment 63
Crossover Assignment 12
NA 4
Sequential Assignment 3
Factorial Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 156
Other 11
Diagnostic 7
Supportive Care 7
Basic Science 5
Prevention 3
NA 2
Screening 1

Observational Studies

Studies by Country

Country Study_Count
United States 25
France 16
NA 7
Hungary 2
Israel 2
Turkey 2
Australia 1
Austria 1
Canada 1
China 1
Egypt 1
Hong Kong 1
Italy 1
Italy|Austria|Belgium|Czech Republic|France|Germany|Greece|Israel|Netherlands|Norway|Portugal|Spain|Switzerland|Turkey|United Kingdom 1
Japan 1
Netherlands 1
Sweden 1
Switzerland 1
Taiwan 1

Sites per Study

Site_count Study_Count
1 61
2 2
3 1
4 1
25 1
50 1

Enrollment Metrics

Measure Observational
Min 7.0000
1st Qu 50.0000
Median 120.0000
Mean 582.6462
3rd Qu 226.0000
Max 20000.0000

Observation Model

observational_model Study_Count
Cohort 37
Case-Control 8
Case Control 8
Case-Only 5
Other 5
NA 3
Case-Crossover 1

Time Perspective

time_perspective Study_Count
Prospective 45
Cross-Sectional 14
Retrospective 4
NA 3
Other 1

Registries

Studies by Country

Country Study_Count
United States 4
Austria 1
Israel 1

Sites per Study

Site_count Study_Count
1 6

Enrollment Metrics

Measure Registries
Min 32.0000
1st Qu 165.0000
Median 400.0000
Mean 408.6667
3rd Qu 500.0000
Max 1000.0000

Registry Model

observational_model Study_Count
Cohort 4
Case-Only 1
Other 1

Time Perspective

time_perspective Study_Count
Prospective 6

Follow-up

target_duration Study_Count
10 Years 3
20 Years 1
36 Months 1
6 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT02212249 Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis https://ClinicalTrials.gov/show/NCT02212249 Completed University Hospital, Grenoble 2016-03-31
NCT04166552 Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis https://ClinicalTrials.gov/show/NCT04166552 Recruiting Emerald Health Pharmaceuticals Inc. 2021-03-31
NCT04137224 Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc) https://ClinicalTrials.gov/show/NCT04137224 Recruiting CSL Behring 2021-08-31
NCT03976648 A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03976648 Active, not recruiting Galapagos NV 2022-05-31
NCT03798366 A Clinical Study to Test How Effective and Safe GLPG1690 is for Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03798366 Completed Galapagos NV 2020-05-21
NCT03388255 Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma Diseases https://ClinicalTrials.gov/show/NCT03388255 Active, not recruiting Mastelli S.r.l 2019-09-30
NCT03374618 Neutrophil Extracellular Traps in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03374618 Recruiting CHU de Reims 2021-10-06
NCT03294616 Transcutaneous Electroacupuncture for Gastric Complications of Scleroderma https://ClinicalTrials.gov/show/NCT03294616 Completed Johns Hopkins University 2019-06-30
NCT03274076 Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) https://ClinicalTrials.gov/show/NCT03274076 Completed University of Michigan 2019-04-08
NCT03270722 Functional Luminal Imaging Probe (FLIP) Topography Use in Patients With Scleroderma and Trouble Swallowing https://ClinicalTrials.gov/show/NCT03270722 Recruiting Stanford University 2020-05-31
NCT03222492 Brentuximab Vedotin for Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03222492 Recruiting National Institute of Allergy and Infectious Diseases (NIAID) 2020-09-30
NCT03221257 Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate https://ClinicalTrials.gov/show/NCT03221257 Recruiting University of California, Los Angeles 2021-12-31
NCT03198689 Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03198689 Recruiting Lawson Health Research Institute 2021-03-01
NCT03120533 Treprostinil Iontophoresis in Systemic Sclerosis Digital UlcErations. A Proof of Concept Study https://ClinicalTrials.gov/show/NCT03120533 Completed University Hospital, Grenoble 2019-06-03
NCT03092024 Scleroderma Patient-centered Intervention Network (SPIN) Hand Program Feasibility Study https://ClinicalTrials.gov/show/NCT03092024 Completed Lady Davis Institute 2017-10-17
NCT03060551 Injection of Autologous Adipose-derived Stromal Vascular Fraction in the Finger of Systemic Sclerosis Patients https://ClinicalTrials.gov/show/NCT03060551 Active, not recruiting Seoul St. Mary’s Hospital 2020-03-31
NCT03059979 The Effect of High Dose Methylprednisolone on Nailfold in Early Systemic Sclerosis ( SSc ) https://ClinicalTrials.gov/show/NCT03059979 Recruiting Radboud University 2021-07-01
NCT03058887 The Effects of Exercise in Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03058887 Completed Sheffield Hallam University 2018-09-30
NCT03041025 Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03041025 Active, not recruiting GlaxoSmithKline 2020-07-02
NCT03027674 Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud https://ClinicalTrials.gov/show/NCT03027674 Completed Pontificia Universidad Catolica de Chile 2016-08-31
NCT03007004 Effect and Safety of Local Injection of Botulinum Toxin Type B Against Digital Ulcer in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03007004 Completed Gunma University 2019-05-14
NCT02975960 ADMSCs for the Treatment of Systemic Sclerosis https://ClinicalTrials.gov/show/NCT02975960 Completed The Catholic University of Korea 2017-10-30
NCT02921971 Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis https://ClinicalTrials.gov/show/NCT02921971 Completed Sanofi 2019-01-14
NCT02915835 Riociguat in Scleroderma Associated Digital Ulcers https://ClinicalTrials.gov/show/NCT02915835 Completed University of Michigan 2018-07-24
NCT02896205 Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease https://ClinicalTrials.gov/show/NCT02896205 Completed Postgraduate Institute of Medical Education and Research 2017-07-01
NCT02837549 Novel Rehabilitation Strategies to Improve Arm Function in Patients With Scleroderma https://ClinicalTrials.gov/show/NCT02837549 Completed University of Michigan 2017-09-30
NCT02801305 Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers https://ClinicalTrials.gov/show/NCT02801305 Completed Shiraz University of Medical Sciences 2017-01-31
NCT02733978 Ozone Therapy in the Treatment of Digital Ulcers in Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT02733978 Completed Assiut University 2016-08-31
NCT02682511 Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT02682511 Recruiting Cumberland Pharmaceuticals 2020-12-31
NCT02663895 Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT02663895 Completed Stanford University 2020-05-31
NCT02636127 Role of Circulating Cytotoxic Lymphocytes in Endothelial Cell Injury in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT02636127 Completed Assistance Publique Hopitaux De Marseille 2016-07-21
NCT02610842 Hands on - a Hand Care Guide in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT02610842 Completed University of Campinas, Brazil 2015-10-31
NCT02597933 A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis https://ClinicalTrials.gov/show/NCT02597933 Completed Boehringer Ingelheim 2018-10-31
NCT02562079 Vasculopathy, Inflammation and Systemic Sclerosis https://ClinicalTrials.gov/show/NCT02562079 Completed University Hospital, Bordeaux 2016-12-31
NCT02503644 Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis https://ClinicalTrials.gov/show/NCT02503644 Completed Inventiva Pharma 2018-10-31
NCT02494401 Taking Charge of Systemic Sclerosis https://ClinicalTrials.gov/show/NCT02494401 Completed University of Michigan 2017-07-28
NCT02480335 The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT02480335 Completed University Medical Center Groningen 2018-07-30
NCT02472743 Light Treatment for Scleroderma Finger Ulcers https://ClinicalTrials.gov/show/NCT02472743 Completed University of Manchester 2016-01-31
NCT02465437 Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT02465437 Active, not recruiting Corbus Pharmaceuticals Inc. 2016-10-31
NCT02453256 A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc) https://ClinicalTrials.gov/show/NCT02453256 Completed Hoffmann-La Roche 2018-01-15
NCT02426229 Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma https://ClinicalTrials.gov/show/NCT02426229 Completed Medical University of South Carolina 2018-06-30
NCT02396238 Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR) https://ClinicalTrials.gov/show/NCT02396238 Completed Cytori Therapeutics 2017-09-19
NCT02386436 A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of GSK2330811 in Healthy Subjects https://ClinicalTrials.gov/show/NCT02386436 Completed GlaxoSmithKline 2016-04-11
NCT02371005 Oral Manifestations of Systemic Sclerosis https://ClinicalTrials.gov/show/NCT02371005 Recruiting University Hospital, Strasbourg, France 2021-06-30
NCT02370784 Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma https://ClinicalTrials.gov/show/NCT02370784 Active, not recruiting University of Pittsburgh 2018-12-15
NCT02370693 Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT02370693 Recruiting Northwestern University 2020-06-30
NCT02363478 Long Term Effect of Buspirone on Esophageal Function and Esophageal Symptoms in Patients With Systematic Sclerosis (SSc) https://ClinicalTrials.gov/show/NCT02363478 Completed Laikο General Hospital, Athens 2015-09-30
NCT02349009 Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial https://ClinicalTrials.gov/show/NCT02349009 Completed Prism Pharma Co., Ltd. 2016-07-31
NCT02290613 Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) https://ClinicalTrials.gov/show/NCT02290613 Completed Heidelberg University 2017-11-27
NCT02283762 Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT02283762 Completed Bayer 2017-12-15
NCT02260557 Effects of Selexipag in Adults With Raynaud’s Phenomenon Secondary to Systemic Sclerosis https://ClinicalTrials.gov/show/NCT02260557 Completed Actelion 2015-04-30
NCT02228850 Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud’s Phenomenon Secondary to Systemic Sclerosis https://ClinicalTrials.gov/show/NCT02228850 Completed NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) 2015-06-30
NCT02165111 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud’s Syndrome https://ClinicalTrials.gov/show/NCT02165111 Completed Johns Hopkins University 2015-09-30
NCT02161406 A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis https://ClinicalTrials.gov/show/NCT02161406 Completed University of Michigan 2018-09-12
NCT01309997 Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease https://ClinicalTrials.gov/show/NCT01309997 Completed Fred Hutchinson Cancer Research Center 2014-12-31
NCT01295736 Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY https://ClinicalTrials.gov/show/NCT01295736 Completed University Hospital, Lille 2013-08-31
NCT01284322 Fresolimumab In Systemic Sclerosis https://ClinicalTrials.gov/show/NCT01284322 Completed Boston University 2013-06-30
NCT02047708 Zibotentan Better Renal Scleroderma Outcome Study https://ClinicalTrials.gov/show/NCT02047708 Completed University College, London 2017-10-31
NCT01933334 Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD) (LOTUSS) https://ClinicalTrials.gov/show/NCT01933334 Completed Genentech, Inc. 2014-09-30
NCT01895244 Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis https://ClinicalTrials.gov/show/NCT01895244 Recruiting University Hospital Tuebingen 2020-09-30
NCT01878526 Gastroesophageal Reflux Treatment in Scleroderma https://ClinicalTrials.gov/show/NCT01878526 Completed Khon Kaen University 2015-08-31
NCT01862926 Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD https://ClinicalTrials.gov/show/NCT01862926 Active, not recruiting Royal Brompton & Harefield NHS Foundation Trust 2020-08-31
NCT01813578 Effects of Intensive Aerobic and Muscle Endurance Exercise in Patients With Systemic Sclerosis - a Pilot Study https://ClinicalTrials.gov/show/NCT01813578 Completed Karolinska University Hospital 2010-04-30
NCT01813279 Assessment of the Subcutaneous Reinjection of Human Autologous Adipose-derived Stromal Vascular Fraction (Celution® System) in the Hands of Patients Suffering From Systemic Sclerosis https://ClinicalTrials.gov/show/NCT01813279 Completed Assistance Publique Hopitaux De Marseille 2013-11-30
NCT01804959 Clinical Trial of Probiotics in Systemic Sclerosis Associated Gastrointestinal Disease https://ClinicalTrials.gov/show/NCT01804959 Active, not recruiting Singapore General Hospital 2017-11-30
NCT01799174 Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea https://ClinicalTrials.gov/show/NCT01799174 Completed University of Texas Southwestern Medical Center 2015-05-31
NCT01748084 Rituximab in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT01748084 Completed Assistance Publique - Hôpitaux de Paris 2016-04-18
NCT01743612 Laser Speckle Contrast Imaging for Cutaneous Microvascular Dysfunction Detection in Systemic Sclerosis. https://ClinicalTrials.gov/show/NCT01743612 Completed University Hospital, Grenoble 2015-06-30
NCT01670565 Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis https://ClinicalTrials.gov/show/NCT01670565 Completed Hospital for Special Surgery, New York 2015-11-30
NCT01651143 Proof of Biological Activity of SAR100842 in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT01651143 Completed Sanofi 2013-11-30
NCT04335279 Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program https://ClinicalTrials.gov/show/NCT04335279 Active, not recruiting Lady Davis Institute 2020-06-03
NCT01570764 Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease https://ClinicalTrials.gov/show/NCT01570764 Completed Assistance Publique - Hôpitaux de Paris 2018-02-22
NCT01553981 A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma https://ClinicalTrials.gov/show/NCT01553981 Completed Sanjay Gandhi Postgraduate Institute of Medical Sciences 2014-04-30
NCT01538719 IL1-TRAP, Rilonacept, in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT01538719 Completed Boston University 2017-01-31
NCT01532869 A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT01532869 Completed Hoffmann-La Roche 2014-01-31
NCT01488214 Neuropsychiatric Scleroderma Study: Systematic Evaluation of Neuropsychiatric Involvement in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT01488214 Completed University Hospital, Lille 2017-10-24
NCT01487551 An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod) https://ClinicalTrials.gov/show/NCT01487551 Completed Active Biotech AB 2013-02-28
NCT01474109 Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients https://ClinicalTrials.gov/show/NCT01474109 Completed Actelion 2013-11-30
NCT01413100 Scleroderma Treatment With Autologous Transplant (STAT) Study https://ClinicalTrials.gov/show/NCT01413100 Active, not recruiting Fred Hutchinson Cancer Research Center 2025-01-31
NCT01395732 Bosentan in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT01395732 Completed Actelion 2012-11-30
NCT01347008 Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT01347008 Completed Federal University of São Paulo 2013-01-31
NCT04401943 Online Fatigue Intervention Program for People With Scleroderma https://ClinicalTrials.gov/show/NCT04401943 Recruiting University of New Mexico 2021-04-30
NCT04388176 Cold Challenge With C21 in RP https://ClinicalTrials.gov/show/NCT04388176 Active, not recruiting Vicore Pharma AB 2020-10-01
NCT04368403 A Study of KHK4827 in Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT04368403 Active, not recruiting Kyowa Kirin Co., Ltd. 2019-01-31
NCT04336475 The Effect of a Home-based Orofacial Exercise Program on Oral Aperture of Systemic Sclerosis Patients https://ClinicalTrials.gov/show/NCT04336475 Completed Cukurova University 2019-01-31
NCT04274257 A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT04274257 Completed Tokyo University 2019-05-09
NCT04273386 Mouth Handicap in Systemic Sclerosis Questionnaire (MHISS) in Turkish https://ClinicalTrials.gov/show/NCT04273386 Recruiting Istanbul University 2021-01-20
NCT04265144 Cohort of Patients With Systemic Sclerosis Within the Framework of the RESO Reference Centre https://ClinicalTrials.gov/show/NCT04265144 Recruiting University Hospital, Bordeaux 2030-06-30
NCT04214925 Effectiveness of Tai Chi Exercise Program in Scleroderma Patients https://ClinicalTrials.gov/show/NCT04214925 Completed Pamukkale University 2019-06-20
NCT04179292 The Effect of Physiotherapy Program in Scleroderma Patients https://ClinicalTrials.gov/show/NCT04179292 Recruiting Istanbul University 2020-11-21
NCT04138485 Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc) https://ClinicalTrials.gov/show/NCT04138485 Active, not recruiting CSL Behring 2023-11-30
NCT04118725 Muscular Respiratory Involvement and Systemic Sclerosis https://ClinicalTrials.gov/show/NCT04118725 Recruiting Poitiers University Hospital 2021-08-31
NCT04045743 The Benefit of Bermekimab in Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT04045743 Recruiting Hellenic Institute for the Study of Sepsis 2021-02-01
NCT04040322 Intravenous Iloprost in Subjects With Symptomatic Raynaud’s Phenomenon Secondary to Systemic Sclerosis (Phase 3) https://ClinicalTrials.gov/show/NCT04040322 Recruiting Eicos Sciences, Inc. 2020-06-30
NCT03965780 The SPIN - Scleroderma Support Group Leader EDucation Program Trial (SPIN-SSLED) https://ClinicalTrials.gov/show/NCT03965780 Recruiting Lady Davis Institute 2021-02-28
NCT03957681 A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03957681 Active, not recruiting Kyowa Kirin Co., Ltd. 2021-04-01
NCT03914781 SPIN Self-Management Feasibility Trial https://ClinicalTrials.gov/show/NCT03914781 Completed Lady Davis Institute 2019-11-25
NCT03867097 Intravenous Iloprost in Subjects With Symptomatic Raynaud’s Phenomenon Secondary to Systemic Sclerosis (Phase 2) https://ClinicalTrials.gov/show/NCT03867097 Completed Eicos Sciences, Inc. 2019-09-30
NCT03856853 Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease https://ClinicalTrials.gov/show/NCT03856853 Recruiting Beijing Continent Pharmaceutical Co, Ltd. 2021-02-10
NCT03844061 Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03844061 Recruiting Hospital for Special Surgery, New York 2022-02-28
NCT03831438 Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03831438 Active, not recruiting Formation Biologics 2020-06-30
NCT03817424 A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren’s Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis https://ClinicalTrials.gov/show/NCT03817424 Active, not recruiting Viela Bio 2020-06-30
NCT03816345 Nivolumab in Treating Patients With Autoimmune Disorders or Advanced, Metastatic, or Unresectable Cancer https://ClinicalTrials.gov/show/NCT03816345 Recruiting National Cancer Institute (NCI) 2022-08-31
NCT03766243 A Comparison Between Two Educational Methods in the Rehabilitation of the Microstomia in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03766243 Completed IRCSS Istituto Dermopatico dell’Immacolata, Fondazione Luigi Maria Monti 2015-01-31
NCT03742466 Local Injection of Ozone Versus Methylprednisolone Acetate in Carpal Tunnel Syndrome of Scleroderma Patients https://ClinicalTrials.gov/show/NCT03742466 Completed Assiut University 2019-07-30
NCT03726398 CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH https://ClinicalTrials.gov/show/NCT03726398 Recruiting University of Arizona 2020-01-31
NCT03717961 Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03717961 Active, not recruiting Assistance Publique - Hôpitaux de Paris 2020-07-31
NCT03708718 Prednisolone in Early Diffuse Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03708718 Active, not recruiting University of Manchester 2020-06-30
NCT03692299 Effectiveness of Saccharomyces Boulardii for Gastrointestinal Bacterial-overgrowth in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03692299 Completed Coordinación de Investigación en Salud, Mexico 2019-07-26
NCT03675581 A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) https://ClinicalTrials.gov/show/NCT03675581 Completed Boehringer Ingelheim 2019-10-09
NCT03644225 Suction Based Characterization of Healthy and Diseased Skin https://ClinicalTrials.gov/show/NCT03644225 Completed University of Zurich 2019-06-04
NCT03630211 Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03630211 Recruiting University of Pittsburgh 2023-08-01
NCT03614208 Individualized Home-based Exercise Program for Patient With Systemic Sclerosis. https://ClinicalTrials.gov/show/NCT03614208 Completed Universita di Verona 2018-03-01
NCT03593902 Cardiac Safe Transplants for Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03593902 Active, not recruiting Northwestern University 2025-01-31
NCT03588845 The Small Intestine Bacterial Overgrowth Study Pilot https://ClinicalTrials.gov/show/NCT03588845 Recruiting Canadian Scleroderma Research Group 2021-04-01
NCT03575156 Microparticles’s Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03575156 Recruiting University Hospital, Bordeaux 2021-09-30
NCT03561233 Prevalence and Predictors of Proton Pump Inhibitor Partial Response in Gastroesophageal Reflux Disease in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03561233 Completed Khon Kaen University 2018-05-31
NCT03559465 Profibrosing Role of B Lymphocytes in Patients With Systemic Sclerosis. https://ClinicalTrials.gov/show/NCT03559465 Recruiting University Hospital, Lille 2021-12-31
NCT03558854 Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Scleroderma Patients https://ClinicalTrials.gov/show/NCT03558854 Recruiting Federal University of São Paulo 2020-02-29
NCT03537105 Analysis of Cytokine Expression Pattern in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03537105 Completed Poitiers University Hospital 2019-09-04
NCT03531216 Topical Rosemary Oil Application in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03531216 Completed ARCIM Institute Academic Research in Complementary and Integrative Medicine 2016-03-21
NCT03508661 The Scleroderma Patient-centered Intervention Network (SPIN) Support Group Leader Education Program Feasibility Trial https://ClinicalTrials.gov/show/NCT03508661 Completed Lady Davis Institute 2018-08-10
NCT03508375 Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03508375 Recruiting Assistance Publique Hopitaux De Marseille 2021-05-31
NCT03482219 Rehabilitation for Arm Coordination and Hand Movement in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03482219 Active, not recruiting University of Michigan 2020-09-30
NCT03444220 Gut Microbiota Transplantation in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03444220 Completed Oslo University Hospital 2018-05-18
NCT03419208 Scleroderma Patient-centered Intervention Network (SPIN) Hand Program https://ClinicalTrials.gov/show/NCT03419208 Active, not recruiting Lady Davis Institute 2020-03-01
NCT01241383 Effect of Bosentan in Scleroderma Renal Crisis https://ClinicalTrials.gov/show/NCT01241383 Completed Assistance Publique - Hôpitaux de Paris 2015-10-31
NCT01208792 Auto-immunity and Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT01208792 Completed Assistance Publique - Hôpitaux de Paris 2014-07-15
NCT01166139 Nilotinib in the Treatment of Systemic Sclerosis https://ClinicalTrials.gov/show/NCT01166139 Completed Hospital for Special Surgery, New York 2014-07-31
NCT01117298 A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud’s Phenomenon in Scleroderma https://ClinicalTrials.gov/show/NCT01117298 Completed Sanjay Gandhi Postgraduate Institute of Medical Sciences 2010-04-30
NCT01093885 Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis https://ClinicalTrials.gov/show/NCT01093885 Completed University of Pennsylvania 2016-07-31
NCT01086540 Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) https://ClinicalTrials.gov/show/NCT01086540 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2018-06-05
NCT01051960 Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan https://ClinicalTrials.gov/show/NCT01051960 Completed University of California, Los Angeles 2010-06-30
NCT00984932 Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension https://ClinicalTrials.gov/show/NCT00984932 Completed University of Alexandria 2009-07-31
NCT00946738 The Effect of Physical Therapy on Raynaud`s Phenomenon Secondary to Systemic Sclerosis https://ClinicalTrials.gov/show/NCT00946738 Completed Charite University, Berlin, Germany 2008-03-31
NCT00946699 A Study of the Safety and Tolerability of MEDI-551 in Scleroderma https://ClinicalTrials.gov/show/NCT00946699 Completed MedImmune LLC 2012-03-31
NCT00930683 A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma https://ClinicalTrials.gov/show/NCT00930683 Completed MedImmune LLC 2010-05-31
NCT00909337 Early Therapy of Pulmonary Arterial Hypertension https://ClinicalTrials.gov/show/NCT00909337 Completed Medical University of Graz 2010-06-30
NCT00883129 Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) https://ClinicalTrials.gov/show/NCT00883129 Completed University of California, Los Angeles 2015-01-31
NCT00848939 Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT00848939 Completed United Therapeutics 2010-01-31
NCT04387825 Safety Of Fat Micrografts With Adipose-Derived Stromal Vascular Fraction In Hands Of Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT04387825 Completed Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran 2019-05-31
NCT01445821 Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial https://ClinicalTrials.gov/show/NCT01445821 Active, not recruiting Northwestern University 2020-12-31
NCT03919799 KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03919799 Recruiting Kadmon Corporation, LLC 2021-12-31
NCT03740724 A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma https://ClinicalTrials.gov/show/NCT03740724 Recruiting Fibrocell Technologies, Inc. 2020-12-31
NCT03398837 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03398837 Active, not recruiting Corbus Pharmaceuticals Inc. 2020-03-31
NCT03141125 The Effect of Ethanol Extract Physalis Angulata Linn. in Scleroderma Patients With Standard Therapy https://ClinicalTrials.gov/show/NCT03141125 Completed Indonesia University 2017-08-31
NCT03207997 MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients https://ClinicalTrials.gov/show/NCT03207997 Completed Assistance Publique - Hôpitaux de Paris 2018-03-09
NCT01042158 A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT01042158 Completed Johns Hopkins University 2014-11-30
NCT00775463 Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine https://ClinicalTrials.gov/show/NCT00775463 Completed United Therapeutics 2011-03-31
NCT00764309 Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis https://ClinicalTrials.gov/show/NCT00764309 Completed Bristol-Myers Squibb 2010-06-30
NCT00740285 Effectiveness and Safety of Lidocaine for Scleroderma https://ClinicalTrials.gov/show/NCT00740285 Completed Federal University of São Paulo 2006-04-30
NCT00725361 A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma). https://ClinicalTrials.gov/show/NCT00725361 Completed Stanford University 2010-12-31
NCT00707187 Trial of IC351 in Female Scleroderma Patients With Raynaud’s and Sexual Dysfunction https://ClinicalTrials.gov/show/NCT00707187 Completed Rutgers, The State University of New Jersey 2002-07-31
NCT00704665 Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma https://ClinicalTrials.gov/show/NCT00704665 Completed Rutgers, The State University of New Jersey 2001-12-31
NCT00697736 Cardiac Repercussion of Systemic Sclerodermias https://ClinicalTrials.gov/show/NCT00697736 Completed Hospices Civils de Lyon 2014-12-31
NCT00626665 Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud’s Phenomenon in Scleroderma https://ClinicalTrials.gov/show/NCT00626665 Completed Sanjay Gandhi Postgraduate Institute of Medical Sciences 2008-04-30
NCT00624273 Sildenafil for Treatment of Digital Ulcers in Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT00624273 Completed Charite University, Berlin, Germany 2004-11-30
NCT00622895 Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis https://ClinicalTrials.gov/show/NCT00622895 Completed Fred Hutchinson Cancer Research Center 2011-11-01
NCT00613171 Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT00613171 Completed Novartis 2010-01-31
NCT00574613 Efficacy and Safety Study of p144 to Treat Skin Fibrosis in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT00574613 Completed ISDIN 2009-11-30
NCT00555581 Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis https://ClinicalTrials.gov/show/NCT00555581 Completed Hospital for Special Surgery, New York 2011-12-31
NCT00512902 A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT00512902 Completed University of California, Los Angeles 2008-11-30
NCT00506831 Imatinib in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT00506831 Completed Stanford University 2010-09-30
NCT00501995 High Dose Cyclophosphamide for Treatment of Scleroderma https://ClinicalTrials.gov/show/NCT00501995 Completed Johns Hopkins University 2008-07-31
NCT00498615 A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud’s Phenomenon https://ClinicalTrials.gov/show/NCT00498615 Completed Johns Hopkins University 2012-03-31
NCT00479934 Efficacy and Safety of Imatinib in Scleroderma https://ClinicalTrials.gov/show/NCT00479934 Completed University Hospital, Bordeaux 2010-06-30
NCT00476801 UVA1 Light for Treatment of Scleroderma and Similar Conditions https://ClinicalTrials.gov/show/NCT00476801 Completed University of Michigan 2004-02-29
NCT00442611 A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma) https://ClinicalTrials.gov/show/NCT00442611 Completed Stanford University 2011-06-30
NCT00433186 Mycophenolate Mofetil in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT00433186 Completed Boston University 2011-03-31
NCT00378521 Dose Response Study of a Topical Gel for the Treatment of Raynaud’s Phenomenon https://ClinicalTrials.gov/show/NCT00378521 Completed MediQuest Therapeutics NA
NCT00348296 Efficacy and Safety Study of GB-0998 for Treatment of Systemic Sclerosis https://ClinicalTrials.gov/show/NCT00348296 Completed Benesis Corporation 2009-07-31
NCT00333437 Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement https://ClinicalTrials.gov/show/NCT00333437 Completed University of California, San Francisco 2009-01-31
NCT00319033 Open-label Study With Bosentan in Interstitial Lung Disease https://ClinicalTrials.gov/show/NCT00319033 Completed Actelion 2006-02-28
NCT00318188 Effects of a Personalized Standardized Rehabilitation Program in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT00318188 Completed Assistance Publique - Hôpitaux de Paris 2011-12-31
NCT00318175 Effect of Bosentan on Skin Fibrosis in Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT00318175 Completed Heinrich-Heine University, Duesseldorf NA
NCT00278525 Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma https://ClinicalTrials.gov/show/NCT00278525 Completed Northwestern University 2011-09-30
NCT00241189 Rapamycin vs Methotrexate in Diffuse SSc https://ClinicalTrials.gov/show/NCT00241189 Completed University of California, Los Angeles 2006-06-30
NCT00147771 Imiquimod in Children With Plaque Morphea https://ClinicalTrials.gov/show/NCT00147771 Completed The Hospital for Sick Children 2009-09-30
NCT00129428 Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix https://ClinicalTrials.gov/show/NCT00129428 Completed University of Michigan 2009-01-31
NCT00114530 Scleroderma: Cyclophosphamide or Transplantation (SCOT) https://ClinicalTrials.gov/show/NCT00114530 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2016-04-30
NCT00070590 Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma https://ClinicalTrials.gov/show/NCT00070590 Completed Actelion 2005-09-30
NCT00058578 Stem Cell Transplant to Treat Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT00058578 Completed Baylor College of Medicine NA
NCT00043706 Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis https://ClinicalTrials.gov/show/NCT00043706 Completed Sanofi NA
NCT00025818 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome https://ClinicalTrials.gov/show/NCT00025818 Completed Allergan 2003-03-31
NCT00077584 Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma https://ClinicalTrials.gov/show/NCT00077584 Completed Actelion 2005-03-31
NCT00016458 Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis https://ClinicalTrials.gov/show/NCT00016458 Completed Office of Rare Diseases (ORD) NA
NCT00010335 Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders https://ClinicalTrials.gov/show/NCT00010335 Completed Fred Hutchinson Cancer Research Center 2010-07-31
NCT00007267 Psychological Treatments for Scleroderma https://ClinicalTrials.gov/show/NCT00007267 Completed Johns Hopkins University 2006-06-30
NCT00005675 Oral Type I Collagen for Relieving Scleroderma https://ClinicalTrials.gov/show/NCT00005675 Completed National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) 2005-05-31
NCT00004786 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud’s Phenomenon Secondary to Systemic Sclerosis https://ClinicalTrials.gov/show/NCT00004786 Completed Office of Rare Diseases (ORD) NA
NCT00004563 Scleroderma Lung Disease https://ClinicalTrials.gov/show/NCT00004563 Completed The University of Texas Health Science Center, Houston 2013-05-31
NCT00004380 Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis https://ClinicalTrials.gov/show/NCT00004380 Completed Office of Rare Diseases (ORD) NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT04244916 MPA AUC Monitoring in Patients Receiving MMF for Diffuse Cutaneous or Pulmonary Involvement in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT04244916 Recruiting Assistance Publique - Hôpitaux de Paris 2023-05-01
NCT03819777 Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH) https://ClinicalTrials.gov/show/NCT03819777 Recruiting Maastricht University Medical Center 2021-10-31
NCT03340194 Evaluation of Calcinosis in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03340194 Active, not recruiting University Hospital, Lille 2020-06-30
NCT03297580 Itch and Clinacal Caracteristics in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03297580 Completed University Hospital, Brest 2016-03-31
NCT03271333 Description of the Functional Evolution of Diffuse Infiltrating Pneumonia Associated With Systemic Scleroderma. https://ClinicalTrials.gov/show/NCT03271333 Recruiting University Hospital, Lille 2020-08-31
NCT03271320 Evaluation of Aesthetic Impact in Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03271320 Completed University Hospital, Lille 2018-03-31
NCT03269630 New Orleans Pulmonary Hypertension Biobank https://ClinicalTrials.gov/show/NCT03269630 Recruiting Louisiana State University Health Sciences Center in New Orleans 2027-10-31
NCT03268330 Role of Macrophage Migratory Inhibitory Factor in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03268330 Recruiting Assiut University 2020-10-31
NCT03262922 Clinical and Paraclinical Characteristics of the Systemic Scleroderma Cohort According to the Criteria ACR 2013 and the History of Professional Exposure or of Agricultural Environment https://ClinicalTrials.gov/show/NCT03262922 Recruiting Rennes University Hospital 2020-12-31
NCT02835196 Optical Elastography of Systemic Sclerosis Skin https://ClinicalTrials.gov/show/NCT02835196 Completed The University of Texas Health Science Center, Houston 2018-11-01
NCT02789670 Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients https://ClinicalTrials.gov/show/NCT02789670 Recruiting University Hospital, Lille 2020-07-31
NCT02740569 Obstructive Sleep Apnea in Scleroderma and Pulmonary Involvement https://ClinicalTrials.gov/show/NCT02740569 Completed Marmara University 2016-10-01
NCT02655640 The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis https://ClinicalTrials.gov/show/NCT02655640 Completed Universitaire Ziekenhuizen Leuven 2017-03-31
NCT00055055 Study of Families With Twins or Siblings Discordant for Rheumatic Disorders https://ClinicalTrials.gov/show/NCT00055055 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT02339441 Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis https://ClinicalTrials.gov/show/NCT02339441 Completed University of Manchester 2015-12-31
NCT02331225 Endothelial Microparticles in Systemic Sclerosis Pulmonary Hypertension https://ClinicalTrials.gov/show/NCT02331225 Completed Louisiana State University Health Sciences Center in New Orleans 2016-07-31
NCT02298777 Metabolomic Analysis of Systemic Sclerosis https://ClinicalTrials.gov/show/NCT02298777 Recruiting University Hospital, Strasbourg, France 2020-12-31
NCT02105818 Swallowing Difficulties With Medication Intake and Coping Strategies in Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT02105818 Completed University Hospital, Basel, Switzerland 2014-06-30
NCT01270425 Sonographic and Laboratory Evaluation of the Thyroid Gland in Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT01270425 Completed Meir Medical Center 2011-12-31
NCT02006420 Scleroderma ARFI Imaging of the Skin https://ClinicalTrials.gov/show/NCT02006420 Completed University of Michigan 2015-12-31
NCT01931644 At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions https://ClinicalTrials.gov/show/NCT01931644 Recruiting Sanguine Biosciences 2025-08-31
NCT01881529 A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma https://ClinicalTrials.gov/show/NCT01881529 Completed Gilead Sciences 2014-03-31
NCT01848418 Conception of an ICF Core Set for Systemic Sclerosis https://ClinicalTrials.gov/show/NCT01848418 Completed Assistance Publique - Hôpitaux de Paris 2018-03-31
NCT01817361 Oral Health and People With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT01817361 Completed University of Alabama at Birmingham 2010-06-30
NCT01762449 Morbidity and Mortality Follow Up for the Scleroderma Lung Study https://ClinicalTrials.gov/show/NCT01762449 Completed Duke University 2013-06-30
NCT01729611 Endothelial Function in Patients With Scleroderma or Cirrhosis With and Without Pulmonary Hypertension https://ClinicalTrials.gov/show/NCT01729611 Recruiting The Cleveland Clinic 2021-03-31
NCT01673633 Sacroiliitis in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT01673633 Completed Cukurova University NA
NCT01667042 Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough https://ClinicalTrials.gov/show/NCT01667042 Completed Mayo Clinic 2014-06-30
NCT01656447 Scleroderma Registry & Repository at the Hospital for Special Surgery https://ClinicalTrials.gov/show/NCT01656447 Recruiting Hospital for Special Surgery, New York 2030-01-31
NCT01468792 Hemodynamic Changes in Connective Tissue Disease https://ClinicalTrials.gov/show/NCT01468792 Completed Medical University of Graz 2014-02-28
NCT01377090 Digital Ulceration https://ClinicalTrials.gov/show/NCT01377090 Completed Actelion 2012-07-31
NCT04411498 Frequency of Fibromyalgia Syndrome in Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT04411498 Completed Antalya Training and Research Hospital 2019-12-20
NCT04335396 Screening Patients With Diabetes Mellitus for the Presence of Skin Disorder of Scleredema https://ClinicalTrials.gov/show/NCT04335396 Recruiting University of Pecs 2020-05-30
NCT04325217 Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan https://ClinicalTrials.gov/show/NCT04325217 Recruiting Boehringer Ingelheim 2024-03-31
NCT04301596 Assessment of Nutritional Status in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT04301596 Recruiting University Hospital, Montpellier 2023-06-12
NCT04219592 IgG-4 Levels in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT04219592 Active, not recruiting Meir Medical Center 2019-09-30
NCT04132206 Longitudinal Characterization of Microbial Signature in Systemic Sclerosis Patients https://ClinicalTrials.gov/show/NCT04132206 Recruiting Hôpital Européen Marseille 2022-10-08
NCT04066842 Vitamin D in Systemic Sclerosis Patients With Periodontitis https://ClinicalTrials.gov/show/NCT04066842 Completed University of Messina 2019-05-15
NCT03937271 Objective Measurement Methods for Autoimmune Disease and Dry Eye Syndrome https://ClinicalTrials.gov/show/NCT03937271 Active, not recruiting Taipei Veterans General Hospital, Taiwan 2019-05-31
NCT03889509 A Systematic Review of Factors Associated With Pulmonary Arterial Hypertension in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03889509 Active, not recruiting Lawson Health Research Institute 2020-03-01
NCT03816189 Role of Eosinophil in Fibrogenesis of Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03816189 Recruiting University Hospital, Lille 2020-12-31
NCT03678987 Mycophenolate Mofetil Pharmacokinetics in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03678987 Completed Region Skane 2020-01-01
NCT03601520 Mechanisms of Pulmonary Diffusion Limitation in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT03601520 Completed IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy 2017-10-31
NCT03543956 Professional and Personal Toxic Exposure in Systemic Sclerosis : Type, Intensity and Probability of Exposition https://ClinicalTrials.gov/show/NCT03543956 Completed University Hospital, Bordeaux 2019-06-27
NCT03459716 Endothelial Biomarkers of Systemic Sclerosis-associated Pulmonary Hypertension https://ClinicalTrials.gov/show/NCT03459716 Recruiting Louisiana State University Health Sciences Center in New Orleans 2021-04-01
NCT03446339 Pulmonary Hypertension Screening for Rheumatology Patients (SOPHIE) https://ClinicalTrials.gov/show/NCT03446339 Recruiting The University of Hong Kong 2020-08-31
NCT03438032 Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD https://ClinicalTrials.gov/show/NCT03438032 Recruiting Northwestern University 2020-02-01
NCT03411057 Mindfulness Based Stress Reduction in Rheumatic Diseases https://ClinicalTrials.gov/show/NCT03411057 Enrolling by invitation Johns Hopkins University 2021-01-18
NCT01111786 Finger Hardness Measure in Scleroderma https://ClinicalTrials.gov/show/NCT01111786 Completed Mayo Clinic 2013-01-31
NCT00958672 Small Intestinal Mucosal Abnormalities in Systemic Sclerosis Using Capsule Endoscopy https://ClinicalTrials.gov/show/NCT00958672 Completed University Hospital, Rouen 2011-09-30
NCT00860548 SCOT Scleroderma Treatment Alternative Registry (STAR Registry) https://ClinicalTrials.gov/show/NCT00860548 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2016-03-31
NCT00853788 Skin Biopsy Specimens as Biomarkers of Systemic Sclerosis and Response to Mycophenolate Mofetil https://ClinicalTrials.gov/show/NCT00853788 Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 2011-06-30
NCT00843102 Investigation of Coronary and Pulmonary Circulatory Parameters in Systemic Sclerosis https://ClinicalTrials.gov/show/NCT00843102 Completed University of Pecs 2009-12-31
NCT02887495 The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma) https://ClinicalTrials.gov/show/NCT02887495 Recruiting George Washington University 2034-07-31
NCT01959815 Novel Screening Strategies for Scleroderma PAH https://ClinicalTrials.gov/show/NCT01959815 Recruiting University of Michigan 2021-10-31
NCT00668473 Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT00668473 Completed University of Michigan 2008-05-31
NCT00667134 Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic Sclerosis https://ClinicalTrials.gov/show/NCT00667134 Completed University of Michigan 2008-08-31
NCT00566137 Sleep Disturbances and Pulmonary Artery/Aorta Diameter in Scleroderma Patient https://ClinicalTrials.gov/show/NCT00566137 Completed Northwell Health NA
NCT00522002 CLUE Study: Connective Tissue Disease Leg Ulcer Etiology Study https://ClinicalTrials.gov/show/NCT00522002 Completed George Washington University 2010-06-30
NCT00513591 Duke Autoimmunity in Pregnancy Registry https://ClinicalTrials.gov/show/NCT00513591 Completed Duke University 2018-11-19
NCT00377949 Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients https://ClinicalTrials.gov/show/NCT00377949 Completed Georgetown University 2016-01-31
NCT00372398 Premature Coronary Atherosclerosis in Scleroderma https://ClinicalTrials.gov/show/NCT00372398 Completed Tuen Mun Hospital 2010-07-31
NCT00213525 Genesis of Scleroderma: Role of Environmental Factors in 100 Patients With Scleroderma and 300 Controls https://ClinicalTrials.gov/show/NCT00213525 Completed University Hospital, Rouen 2008-10-31
NCT00213460 Small Bowel Motor Impairment in Scleroderma: Results of a Prospective 5-year Manometric Follow-up https://ClinicalTrials.gov/show/NCT00213460 Completed University Hospital, Rouen NA
NCT00074568 Scleroderma Registry https://ClinicalTrials.gov/show/NCT00074568 Recruiting National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) 2022-01-31
NCT00001330 Study of Silicone-Associated Connective Tissue Diseases https://ClinicalTrials.gov/show/NCT00001330 Completed National Institutes of Health Clinical Center (CC) NA
NCT00005317 Idiopathic Pulmonary Fibrosis–Pathogenesis and Staging - SCOR in Occupational and Immunological Lung Diseases https://ClinicalTrials.gov/show/NCT00005317 Completed National Heart, Lung, and Blood Institute (NHLBI) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02851875 Duke Scleroderma Clinic Patient Registry https://ClinicalTrials.gov/show/NCT02851875 Recruiting Duke University 2026-12-31
NCT02530996 Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment https://ClinicalTrials.gov/show/NCT02530996 Completed VA Office of Research and Development 2019-12-31
NCT02062125 Calcinosis in a Single-Center Scleroderma Population https://ClinicalTrials.gov/show/NCT02062125 Active, not recruiting Rutgers, The State University of New Jersey 2022-10-31
NCT01808937 Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository https://ClinicalTrials.gov/show/NCT01808937 Recruiting University of Texas Southwestern Medical Center 2022-01-31
NCT04095351 Connective Tissue Diseases and Lung Manifestations https://ClinicalTrials.gov/show/NCT04095351 Recruiting Medical University Innsbruck 2021-03-01
NCT03473912 Meir Medical Center Rheumatologic Biobank https://ClinicalTrials.gov/show/NCT03473912 Recruiting Meir Medical Center 2037-11-30